在EORTC 1333/PEACE-3试验中强制使用骨保护剂后骨折率下降:镭-223联合恩扎卢胺对比恩扎卢胺单药的安全性分析
PEACE-3为国际前瞻性3期试验,比较镭-223联合恩扎卢胺与恩扎卢胺单药一线治疗转移性去势抵抗性前列腺癌(mCRPC)。独立数据监查委员会在ERA-223结果后强制使用骨保护剂(BPA),BPA使用率从46.1%升至97%。接受BPA者两臂骨折率均显著下降,恩扎卢胺单药组1年骨折率从15.6%降至2.6%。
要点
- PEACE-3试验中强制使用BPA使BPA使用率从46.1%升至97%。
- 接受BPA治疗的患者中,两个研究臂的骨折率均显著下降。
- 恩扎卢胺单药组1年骨折率从15.6%降至2.6%。
核心结论
- PEACE-3中期安全性分析强调mCRPC患者骨折风险高,以及在ARPI时代遵循指南关于BPA给药的必要性。
研究设计与样本
- 国际前瞻性3期PEACE-3试验,比较镭-223联合恩扎卢胺与恩扎卢胺单药一线治疗mCRPC,本文报告中期安全性分析中的骨折率。
主要发现
- 独立数据监查委员会在ERA-223试验(阿比特龙±镭-223)显示两臂骨折率高后,强制PEACE-3试验期间使用BPA,BPA使用率从46.1%升至97%。
- 接受BPA治疗的患者中,两个研究臂的骨折率均显著下降。
- 恩扎卢胺单药组1年骨折率从15.6%降至2.6%(使用BPA后)。
关键数值与推荐
- 国际指南推荐对mCRPC伴骨转移患者给予骨保护剂(BPA)。
- ERA-223试验显示阿比特龙±镭-223两臂骨折率高。
- PEACE-3试验中强制BPA使用后,BPA使用率从46.1%升至97%。
- 恩扎卢胺单药组1年骨折率从15.6%降至2.6%(使用BPA后)。
临床怎么用
- 原文结论强调mCRPC患者骨折风险高,以及在ARPI时代遵循指南关于BPA给药的必要性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bone health is central to the management of patients with metastatic castration-resistant prostate cancer (mCRPC). International guidelines recommend giving a bone-protecting agent (BPA) to patients with mCRPC and bone metastases. However, the data supporting these recommendations were generated before androgen receptor pathway inhibitors (ARPIs) were available. Here we publish for the first time fracture rates from an interim safety analysis of the international prospective phase 3 PEACE-3 trial comparing radium-223 (223Ra) combined with enzalutamide for first-line mCPRC to enzalutamide alone. After results from the ERA-223 trial (abiraterone ± 223Ra) showed a high fracture rate in both arms, the independent data monitoring committee of PEACE-3 mandated BPA use during the trial, which increased BPA use from 46.1% to 97%. For patients who received BPA therapy, fracture rates significantly decreased in both study arms. At 1 year, fractures decreased from 15.6% to 2.6% with a BPA in patients receiving enzalutamide monotherapy. The interim safety analysis of PEACE-3 underscores the high risk of fracture in patients with mCRPC and the necessity of complying with guidelines regarding BPA administration in the ARPI era. The EORTC GUCG-1333 PEACE-3 trial is registered on ClinicalTrials.gov as NCT02194842 and on EudraCT as 2014-001787-36.
引用
- Gillessen S, Tombal B, Turco F, et al. Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis. Eur Urol. 2025. PMID: 39827019. doi:10.1016/j.eururo.2024.11.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。